PHIL.MI IT Equity☆

Pricefull chart →

Mkt cap $1.10B · P/E (FY) 4.2× · 1Y +9.6% · Off 52W high −7.7% · Vol (1Y) 26.7%

Key fundamentalsfull statements →

Philogen S.p.A. is a biotechnology company researching and developing drugs for oncology and chronic inflammatory diseases. Its clinical-stage pipeline includes Nidlegy, Fibromun, Darleukin, Dekavil, and Dodekin, addressing conditions such as melanoma, soft-tissue sarcoma, lung cancer, and inflammatory disorders, plus small-molecule candidates including OncoFAP, OncoACP3, and OncoCAIX for various solid tumors. The company operates in Italy, Switzerland, the United States, and the European Union.

Snapshot

Headline riskfull risk →

Peers

No same-industry peers in the universe for PHIL.MI.